HVTN 807

Phase 1, HIV

This study is assessing an experimental vaccine in combination with an antiretroviral analytical treatment interruption (ATI) in people living with HIV, to better understand the immune responses of people living with HIV after receiving an experimental vaccine, which could help scientists develop a vaccine to prevent HIV.

This study is currently enrolling participants between the ages of 18-60.